当前位置：
X-MOL 学术
›
N. Engl. J. Med.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma
The New England Journal of Medicine ( IF 158.5 ) Pub Date : 2018-01-03 Keith M. Sullivan, Ellen A. Goldmuntz, Lynette Keyes-Elstein, Peter A. McSweeney, Ashley Pinckney, Beverly Welch, Maureen D. Mayes, Richard A. Nash, Leslie J. Crofford, Barry Eggleston, Sharon Castina, Linda M. Griffith, Julia S. Goldstein, Dennis Wallace, Oana Craciunescu, Dinesh Khanna, Rodney J. Folz, Jonathan Goldin, E. William St. Clair, James R. Seibold, Kristine Phillips, Shin Mineishi, Robert W. Simms, Karen Ballen, Mark H. Wener, George E. Georges, Shelly Heimfeld, Chitra Hosing, Stephen Forman, Suzanne Kafaja, Richard M. Silver, Leroy Griffing, Jan Storek, Sharon LeClercq, Richard Brasington, Mary E. Csuka, Christopher Bredeson, Carolyn Keever-Taylor, Robyn T. Domsic, M. Bashar Kahaleh, Thomas Medsger, Daniel E. Furst
The New England Journal of Medicine ( IF 158.5 ) Pub Date : 2018-01-03 Keith M. Sullivan, Ellen A. Goldmuntz, Lynette Keyes-Elstein, Peter A. McSweeney, Ashley Pinckney, Beverly Welch, Maureen D. Mayes, Richard A. Nash, Leslie J. Crofford, Barry Eggleston, Sharon Castina, Linda M. Griffith, Julia S. Goldstein, Dennis Wallace, Oana Craciunescu, Dinesh Khanna, Rodney J. Folz, Jonathan Goldin, E. William St. Clair, James R. Seibold, Kristine Phillips, Shin Mineishi, Robert W. Simms, Karen Ballen, Mark H. Wener, George E. Georges, Shelly Heimfeld, Chitra Hosing, Stephen Forman, Suzanne Kafaja, Richard M. Silver, Leroy Griffing, Jan Storek, Sharon LeClercq, Richard Brasington, Mary E. Csuka, Christopher Bredeson, Carolyn Keever-Taylor, Robyn T. Domsic, M. Bashar Kahaleh, Thomas Medsger, Daniel E. Furst
Myeloablative autologous hematopoietic stem-cell transplantation achieved long-term benefits in patients with scleroderma, including improved event-free and overall survival, at a cost of increased expected toxicity. Rates of treatment-related death and post-transplantation use of DMARDs were lower than those in previous reports of nonmyeloablative transplantation. (Funded by the National Institute of Allergy and Infectious Diseases and the National Institutes of Health; ClinicalTrials.gov number, NCT00114530.)
中文翻译：
重度硬皮病的清髓自体干细胞移植
清髓性自体造血干细胞移植在硬皮病患者中获得了长期益处，包括改善了无事件发生率和总体生存率，但以增加的预期毒性为代价。与治疗相关的死亡和移植后使用DMARDs的比率低于以前非清髓性移植的报道。（由美国国家过敏和传染病研究所和美国国立卫生研究院资助； ClinicalTrials.gov编号，NCT00114530。）
更新日期：2018-01-04
中文翻译：
重度硬皮病的清髓自体干细胞移植
清髓性自体造血干细胞移植在硬皮病患者中获得了长期益处，包括改善了无事件发生率和总体生存率，但以增加的预期毒性为代价。与治疗相关的死亡和移植后使用DMARDs的比率低于以前非清髓性移植的报道。（由美国国家过敏和传染病研究所和美国国立卫生研究院资助； ClinicalTrials.gov编号，NCT00114530。）
京公网安备 11010802027423号